MAPT and Cognitive impairment: Tau inclusions are associated with neurodegeneration in AD, with supportive evidence arising from immunohistochemical studies showing an association between the extent of tau pathology and cognitive impairment [3,4], which is not evident with respect to Aβ plaque burden.